Welcome to our dedicated page for IR-MED news (Ticker: IRME), a resource for investors and traders seeking the latest updates and insights on IR-MED stock.
IR-MED Inc. develops non-invasive, AI-powered infrared spectrographic medical-device technology for clinical decision support. Company news centers on its platform for assessing tissue, skin and blood-related biomarkers beneath the surface, with recurring updates on PressureSafe™ for pressure injury assessment and DiaSafe™ for diabetic foot ulcer assessment.
Coverage also includes clinical studies and presentations, collaborations with healthcare institutions, grants supporting product development, shareholder updates, financing needs, intellectual-property references and leadership or governance changes. PressureSafe™ is described by the company as a handheld, skin-color-agnostic decision support device for assessing pressure injuries before visible skin breakdown.
IR-MED Inc. (OTCQB:IRME) has received a $500,000 grant from the Israel Innovation Authority to develop DiaSafe™, a device for early detection of diabetic foot ulcers. This marks the company's second IIA grant after peer review. DiaSafe™ uses AI-driven spectrographic analysis to provide non-invasive, real-time optical readings of biomarkers. The 13-month development is on schedule, with computer simulations completed and hardware construction underway.
Diabetic foot ulcers affect up to 183 million people globally, with 37 million potentially requiring amputation. Early detection can significantly improve patient outcomes and reduce healthcare costs in a $10 billion global treatment market. IR-MED's platform technology also powers PressureSafe™, a device for early pressure injury detection, expected to launch in the U.S. in H2 2024.
IR-MED has published positive results from a usability study of its PressureSafe™ device, performed in collaboration with Clalit, Israel's largest HMO. The study, which included 924 scans on 154 body locations, demonstrated that PressureSafe™ could reduce pressure injuries by 50%. The device achieved 92% sensitivity and 88% specificity in detecting Stage 1 and suspected deep tissue injury pressure injuries. PressureSafe™, which uses AI-driven infra-red spectroscopy, has received FDA listing confirmation. The findings were also presented at the National Pressure Injury Advisory Panel (NPIAP) 2024 Annual Conference.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.